Edwards Lifesciences Stock - CEO executes small preset share sale
18.06.2026 - 17:42:45 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:40 CET. Details in the imprint.
Edwards Lifesciences (US28176E1082) has disclosed a small insider transaction by CEO Bernard Zovighian in a new SEC filing. According to a recent investing.com summary of the Form 4, the chief executive sold 523 shares under a pre-arranged Rule 10b5-1 plan, while retaining a much larger stake.
All news and background on Edwards Lifesciences stock
Track recent filings, earnings and market data on Edwards Lifesciences in our dedicated topic section and via the company’s own investor-relations pages.
What the Form 4 shows
The latest Form 4 filing details a sale of 523 Edwards Lifesciences shares at an average price of $87.92, totaling about $45,982. The transaction date is reported as 06/17/2026, with the shares sold indirectly via a trust.
The CEO executed the trade under a Rule 10b5-1 plan adopted on 12/12/2025, signaling that it was pre-scheduled rather than opportunistic. After the transaction, the trust still holds more than 11,500 shares, while additional shares are held directly and in a 401(k).
How the chart looks this Thursday
On this Thursday, Edwards Lifesciences shares continue to trade in the upper half of their 12-month range, supported by earlier earnings strength. First-quarter 2026 revenue grew 12.7% year-on-year on a constant-currency basis to $1.65 billion, with EPS up 22% to $0.78.
That stronger operating performance earlier in the year has underpinned a recovery in the stock from its lows of 2025, even if day-to-day moves remain sensitive to broader medtech sentiment. Against this backdrop, the small preset CEO sale looks more like portfolio housekeeping than a directional signal.
How Edwards Lifesciences makes money
Edwards Lifesciences generates most of its revenue from heart-valve therapies and critical-care monitoring solutions for hospitals worldwide. Its portfolio is centered on transcatheter aortic valve replacement systems, surgical heart valves and hemodynamic monitoring technologies used in intensive-care settings.
Where the stock trades today
Edwards Lifesciences stock (US28176E1082) trades on the New York Stock Exchange under the ticker EW at $87.92 as of 06/18/2026, 17:40 CET.
Key facts on Edwards Lifesciences stock
- Company: Edwards Lifesciences Corp.
- ISIN: US28176E1082
- WKN: 936853
- Ticker: EW
- Venue: NYSE
- Price (as of 06/18/2026, 17:40 CET): 87.92 USD
- Market cap: 51,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care - Medical Devices
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
